Overview

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy

Status:
Completed
Trial end date:
2021-01-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the reduction in signs and symptoms of joint disease.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium